European Movers: Puma (PUM GY) +21.0%, Sage (SGE LN) +3.6%, Roche (ROG SW) +1.0%, Siemens (SIE GY) -0.3%, Alstom (ALO FP) -2.1%, Evoke (EVK LN) -7.7%

Alstom (ALO FP) downgraded to Reduce from Hold at Kepler Cheuvreux.

Evoke (EVK LN) - Q4 (GBP): Revenue 464mln, +7% Y/Y (-3% in constant currency). FY25 Adjusted EBITDA expected to be in line with market expectations. No forward looking statement as the Co. continues to review strategic operations (as previously announced).

Puma (PUM GY) - ANTA Sports to acquire a 29% stake in Puma. Says the deal brings proven growth track record to help unlock Pumaʼs potential globally including in China. Has no current plans to make a takeover offer for Puma.

Roche (ROG SW) - Genentech posted positive topline results from CT388-103, a Phase II clinical trial of CT-388, an investigational dual GLP-1/GIP receptor agonist being developed for the treatment of obesity. 

Sage (SGE LN) - Q1'26 (GBP): Total Revenue 674mln (prev. 610mln Y/Y). "We reiterate our full-year guidance, as set out in our FY25 results announcement, and remain focused on driving efficient, sustainable growth and long-term value for all stakeholders." 

Siemens (SIE GY) downgraded to Reduce from Hold by Kepler Cheuvreux.

Puma's significant jump follows news of ANTA Sports acquiring a 29% stake, suggesting potential for enhanced growth, particularly in the China market. Conversely, Alstom and Siemens faced downgrades, indicating negative sentiment that could pressure their stock performance in the near term. Meanwhile, Sage's solid revenue growth and Roche's positive trial results show strength in their respective sectors, which could lead to broader sector implications.